Neu 120 / Neurim - LARVOL DELTA

Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia (clinicaltrials.gov) - P1/2; N=8; Terminated; Sponsor: Neurim Pharmaceuticals Ltd.; N=20 -> 8 ; Active, not recruiting -> Terminated

Enrollment change • Trial termination • Biosimilar • Growth Hormone • Immunology • Parkinson's Disease